## Ian G Mckeith

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6821652/publications.pdf

Version: 2024-02-01

346 papers 35,118 citations

92 h-index 174 g-index

356 all docs

356 docs citations

356 times ranked

21474 citing authors

#	Article	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.1	2,805
2	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	3.9	2,497
3	Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, The, 2000, 356, 2031-2036.	13.7	1,138
4	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	3.9	885
5	Dementia with Lewy bodies. Lancet Neurology, The, 2004, 3, 19-28.	10.2	645
6	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
7	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, The, 2007, 6, 305-313.	10.2	598
8	Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 2004, 127, 791-800.	7.6	544
9	Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behavioral and Brain Sciences, 2005, 28, 737-757.	0.7	441
10	Operational criteria for senile dementia of Lewy body type (SDLT). Psychological Medicine, 1992, 22, 911-922.	4.5	434
11	Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience, 1995, 64, 385-395.	2.3	396
12	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neurolmage, 2003, 18, 895-907.	4.2	388
13	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	9.0	374
14	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.1	365
15	A Longitudinal Study of Hippocampal Volume, Cortisol Levels, and Cognition in Older Depressed Subjects. American Journal of Psychiatry, 2004, 161, 2081-2090.	7.2	349
16	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. International Journal of Geriatric Psychiatry, 2001, 16, 528-536.	2.7	321
17	The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. British Journal of Psychiatry, 2000, 177, 252-256.	2.8	319
18	Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. British Journal of Psychiatry, 2009, 194, 212-219.	2.8	313

#	Article	IF	CITATIONS
19	Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies. Archives of Neurology, 2004, 61, 919.	4.5	312
20	How to diagnose dementia with Lewy bodies: State of the art. Movement Disorders, 2005, 20, S11-S20.	3.9	304
21	Education, the brain and dementia: neuroprotection or compensation?. Brain, 2010, 133, 2210-2216.	7.6	302
22	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
23	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 2006, 21, 1899-1907.	3.9	290
24	Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Movement Disorders, 2001, 16, 1171-1174.	3.9	289
25	Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. NeuroReport, 1994, 5, 747-749.	1.2	262
26	5HT2 receptor changes in major depression. Biological Psychiatry, 1990, 27, 489-496.	1.3	253
27	Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1176-1181.	1.9	250
28	Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Medicine, 2009, 6, e1000180.	8.4	238
29	Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia. Journal of Neurochemistry, 1999, 73, 1590-1597.	3.9	231
30	The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiology of Disease, 2007, 25, 561-570.	4.4	231
31	Anxiety, depression and psychosis in vascular dementia: prevalence and associations. Journal of Affective Disorders, 2000, 59, 97-106.	4.1	220
32	Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia. Alzheimer Disease and Associated Disorders, 1993, 7, 69-79.	1.3	219
33	Systematic Review and Meta-Analysis Show that Dementia with Lewy Bodies Is a Visual-Perceptual and Attentional-Executive Dementia. Dementia and Geriatric Cognitive Disorders, 2003, 16, 229-237.	1.5	206
34	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	10.8	203
35	Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. Brain, 2005, 128, 1267-1276.	7.6	201
36	Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. American Journal of Psychiatry, 2015, 172, 731-742.	7.2	200

#	Article	IF	Citations
37	Twoâ€Year Progression from Mild Cognitive Impairment to Dementia: To What Extent Do Different Definitions Agree?. Journal of the American Geriatrics Society, 2008, 56, 1424-1433.	2.6	199
38	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2017, 31, 147-168.	4.0	198
39	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
40	Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurology, The, 2005, 4, 735-742.	10.2	192
41	The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimer's Research and Therapy, 2014, 6, 46.	6.2	181
42	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathologica, 2017, 134, 459-473.	7.7	180
43	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. Journal of Clinical Psychiatry, 2005, 66, 504-514.	2.2	178
44	Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System. Dementia and Geriatric Cognitive Disorders, 2002, 13, 183-192.	1.5	173
45	Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. European Journal of Pharmacology, 2000, 393, 215-222.	3.5	172
46	A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 615-622.	6.4	172
47	Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology, 2000, 48, 868-876.	5.3	171
48	Dementia with Lewy bodies. British Journal of Psychiatry, 2002, 180, 144-147.	2.8	171
49	TDPâ€43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathology, 2017, 27, 472-479.	4.1	170
50	Cognitive Performance in Hypertensive and Normotensive Older Subjects. Hypertension, 2000, 36, 1079-1082.	2.7	168
51	Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease. Archives of Neurology, 2001, 58, 977.	4.5	167
52	New evidence on the management of Lewy body dementia. Lancet Neurology, The, 2020, 19, 157-169.	10.2	167
53	Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial. International Psychogeriatrics, 2001, 13, 199-205.	1.0	155
54	Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience, 2000, 98, 79-87.	2.3	154

#	Article	IF	CITATIONS
55	Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2006, 14, 153-160.	1.2	153
56	Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A crossâ€sectional comparative study. Movement Disorders, 2003, 18, 884-889.	3.9	151
57	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
58	Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 164-171.	2.3	149
59	Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 2006, 20, 732-755.	4.0	145
60	The Natural History of Psychosis and Depression in Dementia With Lewy Bodies and Alzheimer's Disease. Journal of Clinical Psychiatry, 2001, 62, 46-49.	2.2	145
61	SPECTRUM OF PARKINSON'S DISEASE, PARKINSON'S DEMENTIA, AND LEWY BODY DEMENTIA. Neurologic Clinics, 2000, 18, 865-883.	1.8	138
62	Regional cerebral blood flow in Parkinson's disease with and without dementia. NeuroImage, 2003, 20, 1309-1319.	4.2	136
63	Diagnostic accuracy of <sup>123</sup> I-FP-CIT SPECT in possible dementia with Lewy bodies. British Journal of Psychiatry, 2009, 194, 34-39.	2.8	135
64	Clinical prevalence of Lewy body dementia. Alzheimer's Research and Therapy, 2018, 10, 19.	6.2	135
65	Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy-Confirmed Dementia With Lewy Bodies. American Journal of Psychiatry, 2004, 161, 843-849.	7.2	130
66	Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International Journal of Geriatric Psychiatry, 2000, 15, 387-392.	2.7	129
67	What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. International Journal of Geriatric Psychiatry, 2003, 18, 988-993.	2.7	129
68	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
69	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	10.2	124
70	Dementia with Lewy bodies. Seminars in Clinical Neuropsychiatry, 2003, 8, 46-57.	1.9	124
71	Olanzapine in dementia with Lewy bodies: a clinical study. International Journal of Geriatric Psychiatry, 1999, 14, 459-466.	2.7	121
72	Is late-life dependency increasing or not? A comparison of the Cognitive Function and Ageing Studies (CFAS). Lancet, The, 2017, 390, 1676-1684.	13.7	121

#	Article	IF	CITATIONS
73	Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease. Annals of the New York Academy of Sciences, 1991, 640, 197-202.	3.8	120
74	5-HT receptor binding in post-mortem brain from patients with affective disorder. Journal of Affective Disorders, 1987, 13, 67-74.	4.1	119
75	Autopsy validation of <sup>123</sup> I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 88, 276-283.	1.1	118
76	Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. BMJ Open, 2013, 3, e001909.	1.9	115
77	Early Cognitive Change in the General Population: How Do Different Definitions Work?. Journal of the American Geriatrics Society, 2007, 55, 1534-1540.	2.6	113
78	Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet, The, 1995, 346, 699.	13.7	111
79	Progression of White Matter Hyperintensities in Alzheimer Disease, Dementia With Lewy Bodies, and Parkinson Disease Dementia: A Comparison With Normal Aging. American Journal of Geriatric Psychiatry, 2006, 14, 842-849.	1.2	108
80	Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathologica, 2021, 141, 159-172.	7.7	107
81	The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 499-503.	2.7	106
82	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiology of Disease, 2006, 23, 481-489.	4.4	105
83	Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2007, 22, 529-535.	2.7	104
84	The Prevalence, Assessment and Associations of Falls in Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1999, 10, 97-103.	1.5	103
85	Dementia with Lewy bodies: findings from an international multicentre study. International Journal of Geriatric Psychiatry, 2000, 15, 1034-1045.	2.7	101
86	A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2005, 20, 938-944.	2.7	101
87	Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neurolmage, 2004, 23, 325-335.	4.2	100
88	A Comparison of Medial and Lateral Temporal Lobe Atrophy in Dementia with Lewy Bodies and Alzheimer's Disease: Magnetic Resonance Imaging Volumetric Study. Dementia and Geriatric Cognitive Disorders, 2001, 12, 198-205.	1.5	98
89	Effects of Hypertension on Attention, Memory, and Executive Function in Older Adults Health Psychology, 2003, 22, 587-591.	1.6	97
90	Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Movement Disorders, 2005, 20, 1571-1576.	3.9	97

#	Article	IF	CITATIONS
91	Clinical neurochemistry: developments in dementia research based on brain bank material. Journal of Neural Transmission, 1998, 105, 915-933.	2.8	96
92	Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. Journal of the Neurological Sciences, 1991, 106, 50-55.	0.6	95
93	Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: Neurochemical and clinical correlates. Psychiatry Research, 1991, 39, 155-165.	3.3	94
94	Revisiting DLB Diagnosis. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 249-253.	2.3	92
95	MRI Study of Caudate Nucleus Volume in Parkinson's Disease with and without Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 16, 57-63.	1.5	88
96	Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1176-1185.	6.4	88
97	Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2004, 18, 94-100.	1.5	87
98	Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages. PLoS ONE, 2015, 10, e0127396.	2.5	86
99	Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics and Genomics, 2003, 13, 231-239.	5.7	85
100	Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. International Journal of Geriatric Psychiatry, 2013, 28, 135-141.	2.7	84
101	Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. Archives of Neurology, 1999, 56, 961.	4.5	82
102	Dementia with Lewy Bodies. Seminars in Neurology, 2007, 27, 042-047.	1.4	82
103	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neuroscience Letters, 2003, 341, 177-180.	2.1	81
104	MRI volumetric correlates of white matter lesions in dementia with lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2000, 15, 911-916.	2.7	80
105	Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Practical Neurology, 2007, 7, 374-382.	1.1	79
106	Quantification and Characterisation of Fluctuating Cognition in Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 327-335.	1.5	77
107	Depression with late onset is associated with right frontal lobe atrophy. Psychological Medicine, 2003, 33, 675-681.	4.5	76
108	Neuropathological Substrates of Dementia and Depression in Vascular Dementia, with a Particular Focus on Cases with Small Infarct Volumes. Dementia and Geriatric Cognitive Disorders, 2000, 11, 59-65.	1.5	75

#	Article	IF	Citations
109	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 512-519.	1.9	<b>7</b> 5
110	Visual cortex in dementia with Lewy bodies: Magnetic resonance imaging study. British Journal of Psychiatry, 2012, 200, 491-498.	2.8	73
111	Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 318-322.	2.2	<b>7</b> 3
112	Postmortem Neurochemical Studies in Depression. Annals of the New York Academy of Sciences, 1986, 487, 128-142.	3.8	72
113	Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Journal of Clinical Psychiatry, 2005, 66, 633-7.	2.2	72
114	Gastrointestinal Absorption of Aluminium in Alzheimer's Disease: Response to Aluminium Citrate. Age and Ageing, 1992, 21, 81-90.	1.6	71
115	Comparison of Extrapyramidal Signs in Dementia With Lewy Bodies and Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 374-379.	1.8	71
116	Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson's disease. Biological Psychiatry, 1998, 44, 765-774.	1.3	70
117	Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathologica, 2011, 121, 365-371.	7.7	70
118	Neurocardiovascular Instability, Hypotensive Episodes, and MRI Lesions in Neurodegenerative Dementia. Annals of the New York Academy of Sciences, 2000, 903, 442-445.	3.8	69
119	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. Journal of Alzheimer's Disease, 2017, 57, 787-795.	2.6	69
120	APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Annals of Neurology, 2005, 58, 436-441.	5.3	68
121	Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behavioural Brain Research, 2005, 161, 299-305.	2.2	68
122	Diagnosing dementia with Lewy bodies. Lancet, The, 1999, 354, 1227-1228.	13.7	67
123	Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Movement Disorders, 2003, 18, 72-79.	3.9	67
124	Pathophysiology of synuclein aggregation in Lewy body disease. Mechanisms of Ageing and Development, 2006, 127, 188-202.	4.6	67
125	Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychological Medicine, 2018, 48, 2384-2390.	4.5	66
126	Simple Standardised NeuropsychologicalAssessments Aid in the Differential Diagnosis of Dementia with Lewy Bodies from Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 104-108.	1.5	65

#	Article	IF	Citations
127	More Severe Functional Impairment in Dementia With Lewy Bodies Than Alzheimer Disease Is Related to Extrapyramidal Motor Dysfunction. American Journal of Geriatric Psychiatry, 2006, 14, 582-588.	1.2	65
128	The Prevalence of Autonomic Symptoms in Dementia and Their Association with Physical Activity, Activities of Daily Living and Quality of Life. Dementia and Geriatric Cognitive Disorders, 2006, 22, 230-237.	1.5	65
129	A Comparison of Computerized and Pencilâ€andâ€Paper Tasks in Assessing Cognitive Function in Communityâ€Dwelling Older People in the Newcastle 85+ Pilot Study. Journal of the American Geriatrics Society, 2007, 55, 1630-1635.	2.6	65
130	Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 31.	6.2	63
131	Clinical use of the DST in a Psychogeriatric Population. British Journal of Psychiatry, 1984, 145, 389-393.	2.8	62
132	Matching-to-Sample Deficits in Patients With Senile Dementias of the Alzheimer and Lewy Body Types. Archives of Neurology, 1992, 49, 1043-1046.	4.5	62
133	A Detailed Phenomenological Comparison of Complex Visual Hallucinations in Dementia With Lewy Bodies and Alzheimer's Disease. International Psychogeriatrics, 1997, 9, 381-388.	1.0	62
134	Accumulation of dipeptide repeat proteins predates that of <scp>TDP</scp> â€43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in <scp><i>C9ORF72</i></scp> gene. Neuropathology and Applied Neurobiology, 2015, 41, 601-612.	3.2	62
135	A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. International Psychogeriatrics, 2008, 20, 1124.	1.0	61
136	Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology, 2003, 60, 1852-1853.	1.1	60
137	Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Research - Neuroimaging, 2005, 139, 79-88.	1.8	60
138	$\hat{l}$ ±-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2109617119.	7.1	60
139	Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiology of Disease, 2006, 21, 50-56.	4.4	59
140	Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. British Journal of Psychiatry, 2011, 199, 492-500.	2.8	59
141	Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Consciousness and Cognition, 2002, 11, 461-474.	1.5	58
142	The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. NeuroImage, 2004, 23, 956-966.	4.2	58
143	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. Neurobiology of Aging, 2006, 27, 433-438.	3.1	58
144	Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. Journal of Neurochemistry, 2012, 123, 298-309.	3.9	58

#	Article	IF	CITATIONS
145	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathologica Communications, 2016, 4, 66.	5.2	58
146	Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2002, 14, 167-175.	1.5	57
147	Operationalisation of Mild Cognitive Impairment: A Graphical Approach. PLoS Medicine, 2007, 4, e304.	8.4	57
148	The Dementia Cognitive Fluctuation Scale, a New Psychometric Test for Clinicians to Identify Cognitive Fluctuations in People with Dementia. American Journal of Geriatric Psychiatry, 2014, 22, 926-935.	1,2	57
149	HLA-DR antigens associated with major genetic risk for late-onset Alzheimer $\hat{E}^{1}\!\!/\!\!4$ s disease. NeuroReport, 1997, 8, 1467-1469.	1.2	56
150	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	3.9	55
151	In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. NeuroImage, 2006, 33, 423-429.	4.2	54
152	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. Movement Disorders, 2018, 33, 503-510.	3.9	52
153	Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychological Medicine, 1999, 29, 181-187.	4.5	51
154	Involvement of $\hat{l}\pm6/\hat{l}\pm3$ neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [125I]- $\hat{l}\pm$ -conotoxin MII binding in the thalamus and striatum Neuroscience Letters, 2004, 372, 220-225.	2.1	51
155	Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 161-167.	1.5	51
156	Nicotinic $\hat{l}\pm4\hat{l}^22$ receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. NeuroImage, 2008, 40, 1056-1063.	4.2	51
157	Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychological Medicine, 2019, 49, 396-402.	4.5	51
158	Lewy Body Dementia – Diagnosis and Treatment. British Journal of Psychiatry, 1995, 167, 709-717.	2.8	50
159	A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. International Journal of Geriatric Psychiatry, 1999, 14, 973-982.	2.7	50
160	The characterisation and impact of †fluctuating†cognition in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 494-498.	2.7	49
161	Singleâ€cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Annals of Neurology, 2009, 66, 792-798.	<b>5.</b> 3	49
162	CYP2D6 is associated with Parkinson??s disease but not with dementia with Lewy Bodies or Alzheimer??s disease. Pharmacogenetics and Genomics, 1999, 9, 31-36.	5.7	48

#	Article	IF	CITATIONS
163	Costâ€effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the) Tj ETQq1	1 0.784314 rgB 2.7	T_{Qverlock
164	Dementia with Lewy bodies. Dialogues in Clinical Neuroscience, 2004, 6, 333-341.	3.7	48
165	How do memory clinics compare with traditional old age psychiatry services?. International Journal of Geriatric Psychiatry, 2001, 16, 837-845.	2.7	47
166	Cholinesterase inhibitors in dementia with Lewy bodiesâ€"a comparative analysis. International Journal of Geriatric Psychiatry, 2007, 22, 890-895.	2.7	47
167	Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychological Medicine, 2018, 48, 1749-1758.	4.5	47
168	The Clinical Trial Protocol of the Metrifonate in ALzheimer's Trial (MALT). Dementia and Geriatric Cognitive Disorders, 1998, 9, 2-7.	1.5	46
169	Frontotemporal Dementia in Elderly Individuals. Archives of Neurology, 2012, 69, 1052.	4.5	46
170	Single Photon Emission Computerised Tomography in Elderly Patients with Alzheimer's Disease and Multi-infarct Dementia. British Journal of Psychiatry, 1993, 163, 597-603.	2.8	45
171	One Year Follow-Up of Parkinsonism in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2000, 11, 219-222.	1.5	44
172	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease $\hat{a} \in \mathbb{C}$ a multicentre RCT. Trials, 2009, 10, 57.	1.6	44
173	Clinicians' ability to diagnose dementia with Lewy bodies is not affected by $\hat{l}^2$ -amyloid load. Neurology, 2015, 84, 496-499.	1.1	44
174	Relationship Between Mitochondria and α-Synuclein. Archives of Neurology, 2012, 69, 385.	4.5	43
175	Synaptic Proteins and Choline Acetyltransferase Loss in Visual Cortex in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2013, 72, 53-60.	1.7	43
176	Mild cognitive impairment in the older population: Who is missed and does it matter?. International Journal of Geriatric Psychiatry, 2008, 23, 863-871.	2.7	42
177	Cognitive Decline and Dementia Risk in Older Adults With Psychotic Symptoms: AÂProspective Cohort Study. American Journal of Geriatric Psychiatry, 2013, 21, 119-128.	1.2	42
178	Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences. International Journal of Geriatric Psychiatry, 2015, 30, 1135-1146.	2.7	42
179	Cholinergic and perfusion brain networks in Parkinson disease dementia. Neurology, 2016, 87, 178-185.	1.1	41
180	Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. International Journal of Geriatric Psychiatry, 2003, 18, 879-886.	2.7	40

#	Article	IF	Citations
181	Development of assessment toolkits for improving the diagnosis of the Lewy body dementias: feasibility study within the DIAMOND Lewy study. International Journal of Geriatric Psychiatry, 2017, 32, 1280-1304.	2.7	39
182	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39
183	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	1.6	39
184	Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Neuroscience Letters, 2001, 303, 33-36.	2.1	38
185	Alpha- and Gamma-Synuclein Proteins Are Present in Cerebrospinal Fluid and Are Increased in Aged Subjects with Neurodegenerative and Vascular Changes. Dementia and Geriatric Cognitive Disorders, 2008, 26, 32-42.	1.5	38
186	Reduced Gastrointestinal Absorption of Calcium in Dementia. Age and Ageing, 1990, 19, 368-375.	1.6	37
187	Neocortical concentrations of neuropeptides in senile dementia of the alzheimer and lewy body type: Comparison with parkinson's disease and severity correlations. Biological Psychiatry, 1991, 29, 357-364.	1.3	37
188	Does visuospatial memory in senile dementia of the Alzheimer type depend on the severity of the disorder?. International Journal of Geriatric Psychiatry, 1992, 7, 427-436.	2.7	37
189	Medial Temporal Lobe Width on CT Scanning in Alzheimer's Disease: Comparison with Vascular Dementia, Depression and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2000, 11, 114-118.	1.5	36
190	Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2005, 20, 776-782.	2.7	36
191	Optimizing Mild Cognitive Impairment for Discriminating Dementia Risk in the General Older Population. American Journal of Geriatric Psychiatry, 2010, 18, 662-673.	1.2	36
192	Alzheimer and Vascular Neuropathological Changes Associated with Different Cognitive States in a Non-Demented Sample. Journal of Alzheimer's Disease, 2012, 29, 309-318.	2.6	36
193	Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 136B, 62-68.	1.7	35
194	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open, 2014, 4, e005122-e005122.	1.9	35
195	Exome sequencing in dementia with Lewy bodies. Translational Psychiatry, 2016, 6, e728-e728.	4.8	35
196	Effects of Apolipoprotein E Genotype on Cortical Neuropathology in Senile Dementia of the Lewy Body and Alzheimer's Disease. Experimental Neurology, 1995, 4, 443-448.	1.7	34
197	The assessment of cognition in visually impaired older adults. Age and Ageing, 2013, 42, 98-102.	1.6	34
198	Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 1131-1139.	2.6	34

#	Article	lF	Citations
199	Impact of Less Common and "Disregarded―Neurodegenerative Pathologies on Dementia Burden in a Population-Based Cohort. Journal of Alzheimer's Disease, 2012, 28, 485-493.	2.6	33
200	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2019, 77, 112-127.	3.1	33
201	Clinical diagnosis of Lewy body dementia. BJPsych Open, 2020, 6, e61.	0.7	33
202	Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. Journal of Neurology, 2007, 254, 907-913.	3.6	32
203	Support and information needs following a diagnosis of dementia with Lewy bodies. International Psychogeriatrics, 2016, 28, 495-501.	1.0	32
204	Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. Movement Disorders, 2017, 32, 414-422.	3.9	32
205	Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open, 2012, 2, e000380.	1.9	31
206	Symptoms associated with Lewy body disease in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2017, 32, 1163-1171.	2.7	31
207	Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The <scp>DIAMOND</scp> Lewy study. International Journal of Geriatric Psychiatry, 2018, 33, 1293-1304.	2.7	31
208	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. Brain, 2018, 141, 2721-2739.	7.6	31
209	Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathologica, 2021, 141, 511-526.	7.7	31
210	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathologica, 2021, 142, 961-984.	7.7	31
211	Driving, dementia and the Driver and Vehicle Licensing Agency: a survey of old age psychiatrists. Psychiatric Bulletin, 2006, 30, 265-268.	0.3	31
212	Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. Neuropathology and Applied Neurobiology, 2005, 31, 522-535.	3.2	30
213	Reaching the population with dementia drugs: what are the challenges?. International Journal of Geriatric Psychiatry, 2007, 22, 627-631.	2.7	30
214	Regional levels of physiological $\hat{l}_{\pm}$ -synuclein are directly associated with Lewy body pathology. Acta Neuropathologica, 2018, 135, 153-154.	7.7	30
215	α2-Macroglobulin polymorphisms in AlzheimerÊ⅓s disease and dementia with Lewy bodies. NeuroReport, 1999, 10, 1507-1510.	1.2	29
216	The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies. NeuroReport, 2000, 11, 297-299.	1.2	29

#	Article	IF	CITATIONS
217	Neuronal Loss and $\hat{l}$ -Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. American Journal of Geriatric Psychiatry, 2017, 25, 595-604.	1.2	29
218	Dementia with Lewy Bodies. Australian and New Zealand Journal of Psychiatry, 1999, 33, 800-808.	2.3	28
219	Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. International Journal of Neuropsychopharmacology, 2007, 10, 231.	2.1	28
220	Neuropsychological aspects of Lewy body dementia. , 1996, , 99-113.		27
221	Nicotinic 123I-5IA-85380 Single Photon Emission Computed Tomography as a Predictor of Cognitive Progression in Alzheimer's Disease and Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2010, 18, 86-90.	1.2	27
222	Dementia with Lewy bodies. Neurology, 2003, 60, 1571-1573.	1.1	26
223	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. Neurobiology of Aging, 2019, 73, 9-20.	3.1	26
224	Inflammation in dementia with Lewy bodies. Neurobiology of Disease, 2022, 168, 105698.	4.4	26
225	Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03. Neuroscience Letters, 1999, 275, 137-140.	2.1	25
226	Do differences in visuospatial ability between senile dementias of the alzheimer and lewy body types reflect differences solely in mnemonic function?. Journal of Clinical and Experimental Neuropsychology, 1995, 17, 35-43.	1.3	24
227	Commentary: DLB and PDD: the same or different? Is there a debate?. International Psychogeriatrics, 2009, 21, 220.	1.0	24
228	Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. Movement Disorders, 2018, 33, 982-991.	3.9	24
229	Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial. Alzheimer's Research and Therapy, 2019, 11, 9.	6.2	24
230	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. Brain Pathology, 2019, 29, 414-424.	4.1	24
231	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. Neurobiology of Aging, 2020, 91, 88-111.	3.1	24
232	A prospective study of dementia with Lewy bodies. Age and Ageing, 1998, 27, 631-636.	1.6	23
233	Senile Dementia of Lewy Body Type and Alzheimer Type Are Biochemically Distinct in Terms of Paired Helical Filaments and Hyperphosphorylated Tau Protein (Part 1 of 2). Dementia and Geriatric Cognitive Disorders, 1994, 5, 215-221.	1.5	22
234	The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients. Dementia and Geriatric Cognitive Disorders, 2005, 19, 357-360.	1.5	22

#	Article	IF	Citations
235	Changes to the lateral geniculate nucleus in A lzheimer's disease but not dementia with L ewy bodies. Neuropathology and Applied Neurobiology, 2016, 42, 366-376.	3.2	22
236	The Impact of Metrifonate Therapy on Caregivers of Patients with Alzheimer's Disease: Results from the MALT Clinical Trial. Journal of the American Geriatrics Society, 2000, 48, 268-274.	2.6	21
237	Dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 531-548.	1.8	21
238	What explains variations in the clinical use of mild cognitive impairment (MCI) as a diagnostic category?. International Psychogeriatrics, 2008, 20, 697-709.	1.0	21
239	Plasma homocysteine and cognitive decline in older hypertensive subjects. International Psychogeriatrics, 2011, 23, 1607-1615.	1.0	21
240	Visual Hallucinations in Eye Disease and Lewy Body Disease. American Journal of Geriatric Psychiatry, 2016, 24, 350-358.	1.2	21
241	Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts. Journal of Neural Transmission, 2017, 124, 671-683.	2.8	21
242	Depression in late life, cognitive decline and white matter pathology in two clinico-pathologically investigated cases. International Journal of Geriatric Psychiatry, 2001, 16, 281-287.	2.7	20
243	Dementia with Lewy bodies. Medical Clinics of North America, 2002, 86, 519-535.	2.5	20
244	Covariance 99mTc-Exametazime SPECT Patterns in Alzheimer's Disease and Dementia with Lewy Bodies: Utility in Differential Diagnosis. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 54-62.	2.3	20
245	Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in Dementia with Lewy bodies. International Psychogeriatrics, 2013, 25, 1917-1928.	1.0	20
246	The challenges of <scp>COVID</scp> â€19 for people with dementia with Lewy bodies and family caregivers. International Journal of Geriatric Psychiatry, 2020, 35, 1431-1436.	2.7	20
247	Profiling conversation in Parkinson's disease with cognitive impairment. Aphasiology, 1999, 13, 407-425.	2.2	19
248	Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. Neuroscience Letters, 1999, 262, 140-142.	2.1	19
249	Senile dementia of lewy body type?a review of clinical and pathological features: Implications for treatment. International Journal of Geriatric Psychiatry, 1995, 10, 919-926.	2.7	17
250	No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer's disease. Neuroscience Letters, 1997, 234, 19-22.	2.1	17
251	Multivariate Spatial Covariance Analysis of <sup>99M</sup> Tc-Exametazime SPECT Images in Dementia with Lewy Bodies and Alzheimer'S Disease: Utility in Differential Diagnosis. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 612-618.	4.3	17
252	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using <sup>123</sup> I-loflupane Injection (DaTscan) Imaging. Journal of Nuclear Medicine, 2014, 55, 1288-1296.	5.0	17

#	Article	IF	Citations
253	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
254	Neuropathological Profile of Mild Cognitive Impairment From a Population Perspective. Alzheimer Disease and Associated Disorders, 2012, 26, 205-212.	1.3	16
255	What is the neuropathological basis of dementia associated with Lewy bodies?. , 1996, , 212-223.		15
256	Do experienced diagnosticians agree about the diagnosis of dementia from survey data? The effects of informants' reports and interviewers' vignettes., 1998, 13, 852-862.		15
257	Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet, The, 1998, 351, 1818.	13.7	15
258	Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?. International Journal of Geriatric Psychiatry, 2006, 21, 719-721.	2.7	15
259	Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. Synapse, 2007, 61, 903-911.	1.2	15
260	Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. Neuroscience Bulletin, 2019, 35, 295-300.	2.9	15
261	Cognitive Decline in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease: A Prospective Cohort Study. American Journal of Geriatric Psychiatry, 2021, 29, 272-284.	1.2	15
262	Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease. Neurology, 2021, 96, e2685-e2693.	1.1	15
263	A follow-up study of elderly depressives and Alzheimer-type dementia?relationship with DST status. International Journal of Geriatric Psychiatry, 1991, 6, 279-286.	2.7	13
264	Dementia with Lewy bodies: relationships to Parkinson's and Alzheimer's diseases., 1996,, 268-286.		13
265	Donepezil and cardiac syncope: case report. International Journal of Geriatric Psychiatry, 2004, 19, 1110-1112.	2.7	13
266	Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1069-1071.	1.9	12
267	Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2016, 31, 765-770.	2.7	12
268	Author response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2018, 90, 300-301.	1.1	12
269	Altered consciousness and transmitter signalling in Lewy body dementia. , 1996, , 397-413.		11
270	Has the management of Alzheimer's disease changed over the past 100 years?. Lancet, The, 2006, 368, 1619-1621.	13.7	11

#	Article	IF	CITATIONS
271	Levodopa use and sleep in patients with dementia with Lewy bodies. Movement Disorders, 2009, 24, 609-612.	3.9	11
272	Alterations in nicotinic $\hat{l}\pm4\hat{l}^22$ receptor binding in vascular dementia using 123I-5IA-85380 SPECT: Comparison with regional cerebral blood flow. Neurobiology of Aging, 2011, 32, 293-301.	3.1	11
273	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. Clinical Neurophysiology, 2020, 131, 2716-2731.	1.5	11
274	Progression of Clinical Features in Lewy Body Dementia Can Be Detected Over 6 Months. Neurology, 2021, 97, e1031-e1040.	1.1	11
275	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2022, 115, 88-108.	3.1	11
276	A Comparative Study of Attentional Deficits in Senile Dementias of Alzheimer and Lewy Body Types. Dementia and Geriatric Cognitive Disorders, 1992, 3, 350-354.	1.5	10
277	Psychotic symptoms in Alzheimer's disease. International Journal of Geriatric Psychiatry, 1992, 7, 341-345.	2.7	10
278	Pathological significance of Lewy bodies in dementia., 1996,, 195-203.		10
279	No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies. NeuroReport, 1997, 8, 3637-3639.	1.2	10
280	Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. Neuropathology and Applied Neurobiology, 2007, 33, 070615220219002-???.	3.2	10
281	APOE and ACE polymorphisms and dementia risk in the older population over prolonged follow-up: 10 years of incidence in the MRC CFA Study. Age and Ageing, 2010, 39, 104-111.	1.6	10
282	Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [123I]-QNB SPECT. Journal of Neurology, 2015, 262, 2144-2153.	3.6	10
283	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10
284	Dementia with Lewy bodies and other difficult diagnoses. International Psychogeriatrics, 2004, 16, 123-127.	1.0	9
285	Transcranial direct current stimulation in Parkinson's disease dementia: A randomised double-blind crossover trial. Brain Stimulation, 2017, 10, 1150-1151.	1.6	9
286	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	6.2	9
287	Cholinergic muscarinic M1/M4 receptor networks in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa098.	3.3	9
288	Distinct cognitive phenotypes in Alzheimer's disease in older people. International Psychogeriatrics, 2013, 25, 1659-1666.	1.0	8

#	Article	IF	CITATIONS
289	Improving the diagnosis and management of Lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. Programme Grants for Applied Research, 2021, 9, 1-120.	1.0	8
290	Supporting clinical research in the NHS in England: the National Institute for Health Research Dementias and Neurodegenerative Diseases Research Network. Alzheimer's Research and Therapy, 2012, 4, 23.	6.2	7
291	Patient and Informant Views on Visual Hallucinations in Parkinson Disease. American Journal of Geriatric Psychiatry, 2015, 23, 970-976.	1.2	7
292	Prospective predictors of decline <i>&gt;v.</i> stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease. Psychological Medicine, 2021, 51, 2590-2598.	4.5	7
293	Detection of Visual Memory and Learning Deficits in Alzheimer's Disease Using the Cambridge Neuropsychological Test Automated Battery. Dementia and Geriatric Cognitive Disorders, 1991, 2, 150-158.	1.5	6
294	Tacrine and symptomatic treatment in Lewy body dementia. , 1996, , 439-448.		6
295	Propofol and electroconvulsive therapy in a patient at risk from acute intermittent porphyria. British Journal of Anaesthesia, 1998, 80, 260-262.	3.4	6
296	Old age psychiatry. British Journal of Psychiatry, 2002, 180, 97-98.	2.8	6
297	Dementia in Parkinson's disease: common and treatable. Lancet Neurology, The, 2004, 3, 456.	10.2	6
298	Author response: Autopsy validation of <sup>123</sup> I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology, 2017, 89, 751-751.	1.1	6
299	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Translational Neurodegeneration, 2022, 11, 24.	8.0	6
300	Lewy bodies and Alzheimer's disease. British Journal of Psychiatry, 1993, 163, 262-263.	2.8	5
301	Dementia with Lewy bodies. Reviews in Clinical Gerontology, 1997, 7, 163-170.	0.5	5
302	Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Clusterâ€Randomized Trial. Movement Disorders, 2021, 36, 143-151.	3.9	5
303	Dementia in the older population is associated with neocortex content of serum amyloid P component. Brain Communications, 2021, 3, fcab225.	3.3	5
304	KEY PAPERS IN GERIATRIC PSYCHIATRY. SERIES EDITOR: ALISTAIR BURNS Correlation of Cholinergic Abnormalities with Senile Plaques and Mental Test Scores in Senile Dementia. E. Perry, B. Tomlinson, G. Blessed, K. Bergmann, P. Gibson and R. Perry,British Medical Journal (1978)2, 1457-59 International Journal of Geriatric Psychiatry, 1996, 11, 765-771.	2.7	4
305	Behavioral and Psychological Symptoms of Dementia and Dementia With Lewy Bodies. International Psychogeriatrics, 2000, 12, 189-193.	1.0	4
306	Galantamine for vascular dementia. Lancet Neurology, The, 2002, 1, 210.	10.2	4

#	Article	IF	CITATIONS
307	Clinical aspects of dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 307-311.	1.8	4
308	Elderly Individuals With FTLD. JAMA Neurology, 2013, 70, 412.	9.0	4
309	Clinical Diagnostic Criteria for Dementia with Lewy Bodies. , 2017, , 59-71.		4
310	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
311	Discharge patterns from a psychogeriatric inpatient unit. International Journal of Geriatric Psychiatry, 1995, 10, 41-46.	2.7	3
312	Management of the noncognitive symptoms of Lewy body dementia., 1996,, 381-396.		3
313	Management of parkinsonism and psychotic depression in a case of acute intermittent porphyria Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 542-542.	1.9	3
314	Introduction. Dementia and Geriatric Cognitive Disorders, 2004, 17, 1-2.	1.5	3
315	Dementia with Lewy bodies: no association of polymorphisms in the human synphilin gene. Neurogenetics, 2004, 5, 251-252.	1.4	3
316	Who will be eligible? An investigation of the dementia population eligible for cholinesterase treatment following the change in NICE guidance. International Journal of Geriatric Psychiatry, 2010, 25, 719-724.	2.7	3
317	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. Journal of Neural Transmission, 2014, 121, 71-78.	2.8	3
318	Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2019, 34, 990-998.	2.7	3
319	Cholinergic therapy and Lewy body dementia. , 1996, , 414-424.		2
320	Regulatory Issues Concerning Behavioral and Psychological Symptoms of Dementia in Europe. International Psychogeriatrics, 2000, 12, 321-326.	1.0	2
321	TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 1. LONG-TERM USE OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA WITH LEWY BODIES: AN OPEN-LABEL TRIAL. International Psychogeriatrics, 2009, 21, 5.	1.0	2
322	Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome: some comments. International Psychogeriatrics, 2010, 22, 680-680.	1.0	2
323	Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments. Journal of Nutrition, Health and Aging, 2010, 14, 664-668.	3.3	2
324	Dementia with Lewy bodies. , 2005, , 603-614.		2

#	Article	IF	CITATIONS
325	Lewy body disease. Current Opinion in Psychiatry, 1995, 8, 252-257.	6.3	1
326	Neurotrophins and the cholinergic system in dementia., 1996,, 468-476.		1
327	What's new in… Psychiatry: dementia with Lewy bodies. Medicine, 2004, 32, 1-4.	0.4	1
328	Still PADing along: Perception and attention remain key factors in understanding complex visual hallucinations. Behavioral and Brain Sciences, 2005, 28, 776-794.	0.7	1
329	Chapter 9 Dementia with Lewy Bodies and Parkinson's Disease Dementia. Blue Books of Neurology, 2007, , 216-238.	0.1	1
330	Dementia with Lewy bodies. British Journal of Psychiatry, 2008, 192, 117-117.	2.8	1
331	How dementia and neurodegenerative disease clinical research networks have enhanced research delivery in England. Clinical Investigation, 2014, 4, 687-691.	0.0	1
332	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy body diseases. Alzheimer's and Dementia, 2020, 16, e045886.	0.8	1
333	Dementia with Lewy Bodies. , 2001, , 180-186.		1
334	Drs. Ballard and McKeith Reply. American Journal of Psychiatry, 2000, 157, 2062-a-2062.	7.2	1
335	The neuroanatomical basis of cognitive deficits in Lewy body dementia. , 1996, , 114-131.		0
336	Clinical heterogeneity in dementia: responders to cholinergic therapy., 1996,, 425-438.		0
337	Dementia with Lewy bodies. Psychiatry (Abingdon, England), 2005, 4, 52-55.	0.2	0
338	Dementia with Lewy bodies. Psychiatry (Abingdon, England), 2008, 7, 20-23.	0.2	0
339	Cortical Lewy body disease: dementia with Lewy bodies and Parkinson's disease with dementia., 2008,, 293-320.		0
340	O5â€03â€04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWA OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. Alzheimer's and Dementia, 2018, 14, P1646.	ARD 0.8	0
341	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinsonâ $\in$ <sup>M</sup> s and Lewy body diseases. Alzheimer's and Dementia, 2020, 16, e045811.	0.8	O
342	Dementia with Lewy Bodies: Clinical Management. , 2001, , 175-179.		0

#	Article	IF	CITATIONS
343	Cholinergic and Monoaminergic Correlates of Clinical Symptoms in Dementia with Lewy Bodies. Advances in Behavioral Biology, 2002, , 491-496.	0.2	O
344	Clinical, Pathological and Neurochemical Characteristics of Lewy Body Dementia. Advances in Behavioral Biology, 1995, , 77-86.	0.2	0
345	Donald Eccleston, FRCPsych, PhD, DSc. BJPsych Bulletin, 2018, 42, 268-269.	1.1	0
346	Psychiatric Tutor—Rumour or Reality?. Bulletin of the Royal College of Psychiatrists, 1984, 8, 202-203.	0.0	0